Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Autor: Christopher J. Harvey, Elizabeth Trehu, Richard Murray, Haley Laken, Johan Baeck, Weidong Zhang, Judith Jimenez, Ali Sepahi, Karen Brown, Rachel McComb, Courtney Hart, Daniel Felitsky, Martin Fan, Heather Cohen, Xiaoying Xiao, Ellen Hooper, Lara McGrath, Yasmin Hashambhoy-Ramsay, Amanda Hanson, Haeseong Park, Mariela Blum Murphy, Kyriakos P. Papadopoulos, Tanguy Y. Seiwert, Osama E. Rahma, Scott S. Tykodi, Howard A. Burris, Geoffrey T. Gibney, Shivaani Kummar, Patricia LoRusso, Russell K. Pachynski, Gerald S. Falchook, Margaret K. Callahan, Justin F. Gainor, Timothy A. Yap
Rok vydání: 2023
DOI: 10.1158/1078-0432.22487579.v1
Popis: Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Databáze: OpenAIRE